Brenig Therapeutics patents new LRRK2 inhibitors for Parkinson’s disease
Nov. 3, 2023
Brenig Therapeutics Inc. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease, among others.